Karolinska Development Put To The Test
This article was originally published in Start Up
Executive Summary
Sweden’s publicly traded Karolinska Development AB has turned a close relationship with one of Europe’s top biomedical research institutions into an investment portfolio of two dozen biotech assets, all built as virtual companies. It’s a twist on the asset financing model that’s gaining attention among biopharma VCs, but KD needs a sale or two soon to make its version work.